XXX - Bifidobacterium breve strain Yakult & Immunodeficiency

A placebo-controlled trial evaluating Bifidobacterium breve Yakult vs placebo in 42 patients with Immunodeficiency under chemotherapy (CT)

Outcome measures:
Effects on infectious complications, natural killer cells, fecal micro flora, fecal organic acid concentrations, and fecal pH

Results:

• The frequency of fever and the use of intravenous antibiotics were lower in the probiotic group than in the placebo group.


• The administration of probiotics promoted the colonization of anaerobes.


• A disruption of the gut microbiota after chemotherapy, particularly the increase in population…